[Off-label use of drug-eluting coronary stents].
Current recommendations of the German Cardiac Society on percutaneous coronary interventions (PCI) summarise the database available for the use of drug-eluting stents (DES) for the treatment of symptomatic coronary artery stenoses. This analysis concludes that the safety and efficacy of drug-eluting stent platforms have been shown in on- and off-label situations. However, stenting with DES should be critically examined and evaluated in each patient. The decision to use a DES depends on the analysis of the individual morbidity, history of cardio-vascular disease and the specific coronary morphology. Patients characterised by a high risk of restenosis following PCI benefit in particular from DES use. In these cases, the off-label implantation of DES is indicated and necessary.
Germing
A
A
Medizinischen Klinik II, Kardiologie und Angiologie, Berufsgenossenschaftliches Universitätsklinikum Bergmannsheil, Bochum
Lindstaedt
M
M
D001807:Blood Vessel Prosthesis / Q000592:standards*; D023903:Coronary Restenosis / Q000517:prevention & control* / Q000601:surgery*; D004343:Drug Implants / Q000592:standards*; D005343:Fibrinolytic Agents / Q000008:administration & dosage*; D005858:Germany; D006801:Humans; D017410:Practice Guidelines as Topic; D015607:Stents / Q000592:standards*
D004343:Drug Implants; D005343:Fibrinolytic Agents